European Antibiotics Market by Drug Class (Beta Lactam & Beta Lactamase, Quinolones, Macrolides, and Others), Drug Origin (Natural, Semisynthetic, and Synthetic), Spectrum of Activity (Broad-spectrum Antibiotic and Narrow-spectrum Antibiotic), and Route of Administration (Oral, Intravenous, and Others): Opportunity Analysis and Industry Forecast, 2019–2027

1.1. Report description

1.2. Key benefits for stakeholders

1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study

2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top investment pockets

3.2.2. Top winning strategies

3.3. Top player positioning, 2019

3.4. Porter’s five forces analysis

3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. Rise in prevalence of infectious diseases

3.5.1.2. Development of novel approaches for new antibiotics for treating bacterial infections

3.5.2. Restraints

3.5.2.1. Development of antibiotic resistance

3.5.2.2. The time taken for the regulatory approval

3.5.3. Opportunities

3.5.3.1. Discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections.

3.5.4. Impact analysis

3.6. Impact of COVID-19 on European Antibiotic Market

CHAPTER 4: EUROPEAN ANTIBIOTIC MARKET, BY DRUG CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. Beta Lactam and Beta Lactamase Inhibitors

4.2.1. Key market trends, growth factors, and opportunities

4.2.2. Market analysis, by country

4.2.3. Market size and forecast, by type

4.2.3.1. Penicillin

4.2.3.1.1. Market size and forecast

4.2.3.2. Cephalosporin

4.2.3.2.1. Market size and forecast

4.2.3.3. Carbapenem

4.2.3.3.1. Market size and forecast

4.2.3.4. Monobactam

4.2.3.4.1. Market size and forecast

4.3. Quinolone

4.3.1. Key market trends, growth factors, and opportunities

4.3.2. Market analysis, by country

4.4. Macrolide

4.4.1. Key market trends, growth factors, and opportunities

4.4.2. Market analysis, by country

4.5. Other

4.5.1. Key market trends, growth factors, and opportunities

4.5.2. Market analysis, by country

CHAPTER 5: EUROPEAN ANTIBIOTIC MARKET, BY DRUG ORIGIN

5.1. Overview

5.1.1. Market size and forecast

5.2. Natural

5.2.1. Market analysis, by country

5.3. Semisynthetic

5.3.1. Market analysis, by country

5.4. Synthetic

5.4.1. Market analysis, by country

CHAPTER 6: EUROPEAN ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY

6.1. Overview

6.1.1. Market size and forecast

6.2. Broad spectrum antibiotics

6.2.1. Market analysis, by country

6.3. Narrow spectrum antibiotics

6.3.1. Market analysis, by country

CHAPTER 7: EUROPEAN ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION

7.1. Overview

7.1.1. Market size and forecast

7.2. Oral

7.2.1. Market analysis, by country

7.3. Intravenous

7.3.1. Market analysis, by country

7.4. Others

7.4.1. Market analysis, by country

CHAPTER 8: EUROPEAN ANTIBIOTIC MARKET, BY COUNTRY

8.1. Europe

8.1.1. Key market trends, growth factors, and opportunities

8.1.2. Market size and forecast, by country

8.1.2.1. Germany

8.1.2.1.1. Germany antibiotic Market, by drug class

8.1.2.1.2. Germany antibiotic market, by drug origin

8.1.2.1.3. Germany antibiotic market, by spectrum of activity

8.1.2.1.4. Germany antibiotic market, by route of administration

8.1.2.2. France

8.1.2.2.1. France antibiotic market, by drug class

8.1.2.2.2. France antibiotic market, by drug origin

8.1.2.2.3. France antibiotic market, by spectrum of activity

8.1.2.2.4. France antibiotic market, by route of administration

8.1.2.3. UK

8.1.2.3.1. UK antibiotic market, by drug class

8.1.2.3.2. UK antibiotic market, by drug origin

8.1.2.3.3. UK antibiotic market, by spectrum of activity

8.1.2.3.4. UK antibiotic market, by route of administration

8.1.2.4. Italy

8.1.2.4.1. Italy antibiotic market, by drug class

8.1.2.4.2. Italy antibiotic market, by drug origin

8.1.2.4.3. Italy antibiotic market, by spectrum of activity

8.1.2.4.4. Italy antibiotic market, by route of administration

8.1.2.5. Spain

8.1.2.5.1. Spain Antibiotic market, by drug class

8.1.2.5.2. Spain antibiotic market, by drug origin

8.1.2.5.3. Spain antibiotic market, by spectrum of activity

8.1.2.5.4. Spain antibiotic market, by route of administration

8.1.2.6. Rest of Europe

8.1.2.6.1. Rest of Europe antibiotic market, by drug class

8.1.2.6.2. Rest of Europe antibiotic market, by drug origin

8.1.2.6.3. Rest of Europe antibiotic market, by spectrum of activity

8.1.2.6.4. Rest of Europe antibiotic market, by route of administration

8.1.3. Europe antibiotics market, by drug class

8.1.4. Europe antibiotics market, by drug origin

8.1.5. Europe antibiotics market, by spectrum of activity

8.1.6. Europe antibiotics market, by route of administration

CHAPTER 9: COMPANY PROFILES

9.1. ABBOTT LABORATORIES

9.1.1. Company overview

9.1.2. Company snapshot

9.1.3. Operating business segments

9.1.4. Product portfolio

9.1.5. Business performance

9.2. ABBVIE INC.(ALLERGEN)

9.2.1. Company overview

9.2.2. Company snapshot

9.2.3. Operating business segments

9.2.4. Product portfolio

9.2.5. Business performance

9.2.6. Key strategic moves and developments

9.3. BAYER AG.

9.3.1. Company overview

9.3.2. Company snapshot

9.3.3. Operating business segments

9.3.4. Product portfolio

9.3.5. Business performance

9.4. F. HOFFMANN-LA ROCHE LTD.

9.4.1. Company overview

9.4.2. Company snapshot

9.4.3. Operating business segments

9.4.4. Product portfolio

9.4.5. Business performance

9.4.6. Key strategic moves and developments

9.5. GLAXOSMITHKLINE PLC

9.5.1. Company overview

9.5.2. Company snapshot

9.5.3. Operating business segments

9.5.4. Product portfolio

9.5.5. Business performance

9.6. MERCK & CO. INC.

9.6.1. Company overview

9.6.2. Company snapshot

9.6.3. Operating business segments

9.6.4. Product portfolio

9.6.5. Business performance

9.6.6. Key strategic moves and developments

9.7. VIATRIS INC.(MYLAN)

9.7.1. Company overview

9.7.2. Operating business segments

9.7.3. Product portfolio

9.7.4. Key strategic moves and developments

9.8. NOVARTIS INTERNATIONAL AG (SANDOZ)

9.8.1. Company overview

9.8.2. Company snapshot

9.8.3. Operating business segments

9.8.4. Product portfolio

9.8.5. Business performance

9.8.6. Key strategic moves and developments

9.9. PFIZER INC.

9.9.1. Company overview

9.9.2. Company snapshot

9.9.3. Operating business segments

9.9.4. Product portfolio

9.9.5. Business performance

9.10. SANOFI

9.10.1. Company overview

9.10.2. Company snapshot

9.10.3. Operating business segments

9.10.4. Product portfolio

9.10.5. Business performance

9.10.6. Key strategic moves and developments

TABLE 01. EUROPEAN ANTIBIOTIC MARKET, BY DRUG CLASS , 2019–2027 ($MILLION)

TABLE 02. BETA LACTAM & BETA LACTAMASE INHIBITORS, BY TYPE, 2019–2027 ($MILLION)

TABLE 03. EUROPEAN ANTIBIOTIC MARKET, BY DRUG ORIGIN, 2019–2027 ($MILLION)

TABLE 04. EUROPEAN ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY, 2019–2027 ($MILLION)

TABLE 05. EUROPEAN ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)

TABLE 06. EUROPEAN ANTIBIOTIC MARKET REVENUE, BY COUNTRY, 2019–2027($MILLION)

TABLE 07. GERMANY STERILE GLOVES MARKET, BY DRUG CLASS , 2019–2027

TABLE 08. GERMANY ANTIBIOTIC MARKET, BY DRUG ORIGIN, 2019–2027($MILLION)

TABLE 09. GERMANY ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY, 2019–2027($MILLION)

TABLE 10. GERMANY ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027($MILLION)

TABLE 11. FRANCE ANTIBIOTIC MARKET, BY DRUG CLASS , 2019–2027

TABLE 12. FRANCE ANTIBIOTIC MARKET, BY DRUG ORIGIN, 2019–2027($MILLION)

TABLE 13. FRANCE ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY, 2019–2027($MILLION)

TABLE 14. FRANCE ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027($MILLION)

TABLE 15. UK ANTIBIOTIC MARKET, BY DRUG CLASS , 2019–2027

TABLE 16. UK ANTIBIOTIC MARKET, BY DRUG ORIGIN, 2019–2027($MILLION)

TABLE 17. UK ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY, 2019–2027($MILLION)

TABLE 18. UK ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027($MILLION)

TABLE 19. ITALY ANTIBIOTIC MARKET, BY DRUG CLASS , 2019–2027

TABLE 20. ITALY ANTIBIOTIC MARKET, BY DRUG ORIGIN, 2019–2027($MILLION)

TABLE 21. ITALY ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY, 2019–2027($MILLION)

TABLE 22. ITALY ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027($MILLION)

TABLE 23. SPAIN ANTIBIOTIC MARKET, BY DRUG CLASS , 2019–2027

TABLE 24. SPAIN ANTIBIOTIC MARKET, BY DRUG ORIGIN, 2019–2027($MILLION)

TABLE 25. SPAIN ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY, 2019–2027($MILLION)

TABLE 26. SPAIN ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027($MILLION)

TABLE 27. REST OF EUROPE ANTIBIOTIC MARKET, BY DRUG CLASS , 2019–2027

TABLE 28. REST OF EUROPE ANTIBIOTIC MARKET, BY DRUG ORIGIN, 2019–2027($MILLION)

TABLE 29. REST OF EUROPE EUROPEAN ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY, 2019–2027($MILLION)

TABLE 30. REST OF EUROPE ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027($MILLION)

TABLE 31. EUROPE ANTIBIOTICS MARKET, BY DRUG CLASS , 2017-2025 ($MILLION)

TABLE 32. EUROPE ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)

TABLE 33. EUROPE ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)

TABLE 34. EUROPE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)

TABLE 35. ABBOTT: COMPANY SNAPSHOT

TABLE 36. ABBOTT: OPERATING SEGMENTS

TABLE 37. ABBOTT: PRODUCT PORTFOLIO

TABLE 38. ABBVIE: COMPANY SNAPSHOT

TABLE 39. ABBVIE: OPERATING SEGMENT

TABLE 40. ABBVIE: PRODUCT PORTFOLIO

TABLE 41. ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 42. BAYER: COMPANY SNAPSHOT

TABLE 43. BAYER: OPERATING SEGMENTS

TABLE 44. BAYER: PRODUCT PORTFOLIO

TABLE 45. ROCHE: COMPANY SNAPSHOT

TABLE 46. ROCHE: OPERATING SEGMENTS

TABLE 47. ROCHE: PRODUCT PORTFOLIO

TABLE 48. GSK: COMPANY SNAPSHOT

TABLE 49. GSK: OPERATING SEGMENTS

TABLE 50. GSK: PRODUCT PORTFOLIO

TABLE 51. MERCK: COMPANY SNAPSHOT

TABLE 52. MERCK: OPERATING SEGMENTS

TABLE 53. MERCK: PRODUCT PORTFOLIO

TABLE 54. VIATRIS: COMPANY SNAPSHOT

TABLE 55. VIATRIS: OPERATING SEGMENTS

TABLE 56. VIATRIS: PRODUCT PORTFOLIO

TABLE 57. NOVARTIS AG: COMPANY SNAPSHOT

TABLE 58. NOVARTIS: OPERATING SEGMENTS

TABLE 59. NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 60. PFIZER: COMPANY SNAPSHOT

TABLE 61. PFIZER: OPERATING SEGMENTS

TABLE 62. PFIZER: PRODUCT PORTFOLIO

TABLE 63. SANOFI: COMPANY SNAPSHOT

TABLE 64. SANOFI: OPERATING SEGMENTS

TABLE 65. SANOFI: PRODUCT PORTFOLIO